Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stocks, par value $0,0001 per share
-
Shares outstanding
-
58.5M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
27M
-
Shares change
-
-2.72M
-
Total reported value, excl. options
-
$66.6M
-
Value change
-
-$4.9M
-
Put/Call ratio
-
0.41
-
Number of buys
-
37
-
Number of sells
-
-43
-
Price
-
$2.46
Significant Holders of BioAtla, Inc. - Common Stocks, par value $0,0001 per share (BCAB) as of Q4 2023
99 filings reported holding BCAB - BioAtla, Inc. - Common Stocks, par value $0,0001 per share as of Q4 2023.
BioAtla, Inc. - Common Stocks, par value $0,0001 per share (BCAB) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27M shares
of 58.5M outstanding shares and own 46.12% of the company stock.
Largest 10 shareholders include Soleus Capital Management, L.P. (4.07M shares), BlackRock Inc. (2.88M shares), TANG CAPITAL MANAGEMENT LLC (2.52M shares), VANGUARD GROUP INC (2.08M shares), MORGAN STANLEY (1.91M shares), Cormorant Asset Management, LP (1.18M shares), DEUTSCHE BANK AG\ (1.13M shares), RENAISSANCE TECHNOLOGIES LLC (988K shares), GEODE CAPITAL MANAGEMENT, LLC (904K shares), and STATE STREET CORP (724K shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.